Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysis

Overview of attention for article published in BioDrugs, August 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

news: 1 news outlet

twitter: 3 X users

Citations

dimensions_citation: 24 Dimensions

Readers on

mendeley: 53 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 11,154 followers.

@tsuchiyam @Nagi_nao でリツキシマブのBSはRAとNHLのシステマティックレビューがあったんですが、全文みれず…。 https://t.co/PzzGz7W4Iq DLBCLのさっきのはざっとしかみてませんが、そんなに大きな問題はなさそうな感じでしたが。もっとデータ出てくると良いですね。

06 Dec 2019

Reply Repost Favourite

Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysis https://t.co/PzzGz7W4Iq

06 Dec 2019

Reply Repost Favourite

RT @Lymphoma_Papers: Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgk…

26 Aug 2019

Reply Repost Favourite

Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis. #lymphoma #lymsm https://t.co/EtwemZON7N

26 Aug 2019

Reply Repost Favourite